When Dr. Knud Abildgaard passes away in 1986, the LEO Foundation assumes total control of the company. LEO worldwide now has 2,500 employees and an annual turnover of BDKK 1.14.
In 1991, LEO Pharma launches two products, which become LEO Pharma's most renowned products throughout the company's history, followed by a launch of the keystone psoriasis product, Daivobet® in 2001.
Success stories in the treatment of psoriasis gain LEO Pharma international recognition – and its psoriasis treatments win prestigious awards from French Medec and Belgian Galein in 1994. The Confederation of Danish Industries chooses LEO Pharma’s latest psoriasis products for its 2003 Product Award. LEO products continue to win awards – most recently in Spain and Germany in 2009.
Celebrating its centenial in 2008, LEO Pharma has grown into a truly global company with affiliates in 26 countries. The LEO products are sold in more than 90 countries and LEO Pharma celebrates its birthday with a record turnover. The factories in Ireland and Denmark hosting the penicillin production since 1945 are torn down, symbolising the end of an era in the history of LEO Pharma and the Danish pharmaceutical industry.
LEO Pharma embarks on new challenges with the launch of an ambitious growth strategy in 2009.